However, in the DATATOP
study, it did not affect the probability that the patient would need levodopa.
This conclusion came from a carefully conducted study supported by the NINDS called DATATOP
(Deprenyl and Tocopherol Antioxidative Therapy for Parkinson's Disease) that examined, over 5 years, the effects of both deprenyl (selegiline) and vitamin F, on early Parkinson's disease.
study in the USA revealed that (-)-deprenyl delayed the onset of disability associated with early, otherwise untreated Parkinson's disease.
Scientists at Massachusetts General Hospital and the Harvard School of Public Health and including physicians at the University of Rochester Medical Center, led the study, which was based on a landmark study known as DATATOP
, which was conducted two decades ago.
It is not yet clear whether deprenyl alone has subtle symptomatic effects that might explain the results of the DATATOP
study, or whether deprenyl has actual neuroprotective properties.